Rituximab-treated rheumatic patients: B-cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Christian AmmitzbøllMarianne Kragh ThomsenJakob Bøgh AndersenJens Magnus Berth JensenMarie-Louise From HermansenAnders Dahl JohannsenMads Lamm LarsenClara Elbæk MistegaardSusan MikkelsenFruzsina SzabadosSigne Risbøl VilsChristian ErikstrupEllen-Margrethe HaugeAnne TroldborgPublished in: Rheumatology (Oxford, England) (2022)
Continuously impaired humoral response to mRNA vaccines was found in most RTX treated patients after a booster dose or revaccination. Seroconversion was observed in approximately one-third of the patients. Measurable B-cells before boosting or revaccination was the strongest predictor of antibody response after boost or revaccination.